| abstract |
This invention relates to the salt of (L) - (+) - tartaric acid 2-amino-N- {1- (2,4-difluoro-benzyloxymethyl) -2-oxo-2- [3-oxo-3a-pyridin-2 -ylmethyl-2- (2,2,2-trifluoroethyl) -2,3,3a, 4,6,7-hexahydro-pyrazolo [4,3-c] pyridin-5-yl] -ethyl} -2-methylpropionamide , which is a means of stimulating the secretion of growth hormone, and as such is suitable for increasing the level of endogenous growth hormone. In another aspect of the present invention, some intermediate compounds have been proposed that are used in the synthesis of the compound mentioned above. The (L) - (+) - tartaric acid salt of the compound of this invention is useful for the treatment and / or prevention of osteoporosis, insulin resistance, and other conditions or diseases associated with growth hormone deficiency. The (L) - (+) - tartaric acid salt of the compound of the present invention is also suitable for treating osteoporosis when used in combination with a bisphosphonate compound; estrogen, premarin and possibly progesterone; an estrogen agonist or antagonist; or calcitonin. In addition, the present invention relates to pharmaceutical compositions. Moreover, this invention relates to methods in which a combination of an α-2 adrenergic agonist and a salt (L) - (+) - tartaric acid of a compound according to this invention is administered to a human or other animal. The international application was published together with an international search report. . |